TY - JOUR
T1 - Polymeric nanoparticle drug delivery technologies for oral delivery applications
AU - Pridgen, Eric M.
AU - Alexis, Frank
AU - Farokhzad, Omid C.
N1 - Publisher Copyright:
© 2015 © Informa UK, Ltd.
PY - 2015/9/2
Y1 - 2015/9/2
N2 - Introduction: Many therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles (NPs) are one technology being developed to enable clinically feasible oral delivery.Areas covered: This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal (GI) barriers using polymeric NPs will be considered, including mucoadhesive biomaterials and targeting of NPs to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations.Expert opinion: There have been many approaches used to overcome the transport barriers presented by the GI tract, but most have been limited by low bioavailability. Recent strategies targeting NPs to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and NPs across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric NP technologies and enable the translation of these technologies to clinical practice.
AB - Introduction: Many therapeutics are limited to parenteral administration. Oral administration is a desirable alternative because of the convenience and increased compliance by patients, especially for chronic diseases that require frequent administration. Polymeric nanoparticles (NPs) are one technology being developed to enable clinically feasible oral delivery.Areas covered: This review discusses the challenges associated with oral delivery. Strategies used to overcome gastrointestinal (GI) barriers using polymeric NPs will be considered, including mucoadhesive biomaterials and targeting of NPs to transcytosis pathways associated with M cells and enterocytes. Applications of oral delivery technologies will also be discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and mucosal vaccinations.Expert opinion: There have been many approaches used to overcome the transport barriers presented by the GI tract, but most have been limited by low bioavailability. Recent strategies targeting NPs to transcytosis pathways present in the intestines have demonstrated that it is feasible to efficiently transport both therapeutics and NPs across the intestines and into systemic circulation after oral administration. Further understanding of the physiology and pathophysiology of the intestines could lead to additional improvements in oral polymeric NP technologies and enable the translation of these technologies to clinical practice.
KW - M cells
KW - chemotherapy
KW - inflammatory bowel disease
KW - insulin
KW - mucoadhesives
KW - mucosal vaccinations
KW - oral delivery
KW - polymeric nanoparticles
KW - transcytosis
UR - http://www.scopus.com/inward/record.url?scp=84939644520&partnerID=8YFLogxK
U2 - 10.1517/17425247.2015.1018175
DO - 10.1517/17425247.2015.1018175
M3 - Artículo de revisión
C2 - 25813361
AN - SCOPUS:84939644520
SN - 1742-5247
VL - 12
SP - 1459
EP - 1473
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 9
ER -